Any takers?
Let's go Yellow!
Posted on 06/01/2015 6:35:41 PM PDT by BenLurkin
Nell Barrie, a spokeswoman for Cancer Research UK, while calling the results "encouraging" and "promising," told CNN that much remains to be learned and the new drugs would not replace any of the existing cancer treatments.
...
But Dr. James Larkin, the lead author of the melanoma study, called the results a game changer.
"We've seen these drugs working in a wide range of cancers, and I think we are at the beginning of a new era in treating cancer,"
Barrie said immunotherapy could offer hope to people with cancers that are otherwise difficult to treat, such as melanoma, advanced lung cancer or cancer that has spread throughout the body.
"We're looking at another weapon in the arsenal," she said.
At the heart of immunotherapy is that cancer -- unlike most other diseases -- is not an invader. It consists instead of the body's own cells gone rogue.
So the immune system is not programmed to target the cancerous cells because it does not recognize them as foreign.
The immunotherapy drugs, Barrie said, "work to switch the immune system back on."
(Excerpt) Read more at cnn.com ...
RE: the lead author of the melanoma study, called the results a game changer.
OK, some questions:
1) How long before it is approved by the foot dragging government?
2) How much will it cost?
I re-read the post and realized one thing — This was done in the UK !! Not the USA.
My prediction:
The Clintons and Streisands of the world will have no trouble receiving it, but you and I will be at the mercy of the Death Panels.
Well, yes. Turning the immune system "back on" against cancer cells risks a wide range of autoimmune diseases. You'd have to craft the dosages very carefully and stay on top of their effects every minute. This won't be easy, but it's certainly promising.
I believe that type of “virus-activated immune response” cancer treatment research might have started in the USA: http://www.businessinsider.com/using-measles-virus-to-treat-cancer-2014-5?op=1
Well, this is the UK - so answer to #1 is probably not as long as it will in the risk averse FDA.
#2 - Billions. Complying with that foot dragging government, clinical trials, paperwork, is very, very costly.
My wife passed from melanoma two years ago this week. She was taking an immunology drug, Yervoy. Yervoy has been used for about five years now. It’s not new. Patient response when she was being treated was all over the map. A few went into a remission that could be described as cure. Life extension with decent health was the response for some 30 to 40 %. My wife fell into the cohort that showed no response at all, a response of 30 to 40 %. I do believe that a cure will result from immunology, but this report is only a beginning.
Wasn`t there a recent discovery of a protein that hyper-activates T-Cells to attack virus and cancer cells? I remember reading this on Drudge Report.
I can’t count the number of promising reports of anti-cancer treatments in laboratories that ultimately fizzle out.
Only given for those 30 and under.
Hope not, not would not doubt it!
We were just talking about this subject yesterday, the 31st.
‘Joe Biden Announces Passing Of Son, Beau Biden.’
This is a ping list for cancer survivors and caregivers to share information. If you would like your name added to or removed from this ping list, please tell us in the comments section at this link (click here). (For the most updated list of names, click on the same link and go to the last comment.)
They are doing this kind of work at MD Anderson in Houston.
My grandson already received immunotherapy last year in his fight against a vicious childhood cancer, neuroblastoma. The cancer is not advancing. We see that as a win. Keep praying with us for 5 year old Eli.
Prayers for Eli.
That is good news! Praying again now for Eli...
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.